HONG KONG, Feb. 13, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody targeting IL-4Rα...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces IND Acceptance for AK139, a Bispecific Antibody Targeting IL-4Rα and ST2 for Respiratory and Skin Diseases )
Also on site :
- Country 'MVP' Refunds Entire Audience Mid-Concert and Fans 'Cannot Believe He Did That'
- Legendary '70s Rock Band’s Song Sparks Fan Theories 50 Years Later
- Trump fija nuevo plazo de negociación de dos semanas y desencadena esfuerzo urgente por reanudar las conversaciones con Irán